✦ LIBER ✦

Outcome of combination therapy with sulfasalazine or 5-aminosalicylates and corticosteroids in a population-based cohort of patients with inflammatory bowel disease

✍ Scribed by Edward V. Loftus; William A. Faubion; William J. Sandborn

Book ID: 119391834
Publisher: Nature Publishing Group
Year: 2001
Tongue: English
Weight: 28 KB
Volume: 96
Category: Article
ISSN: 0002-9270
DOI: 10.1016/s0002-9270(01)03727-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ocular manifestations in a community-bas

Ocular manifestations in a community-based cohort of patients with inflammatory bowel disease

✍ Dídia Bismara Cury; Alan C. Moss 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 2 views

## Background: Ophthalmologic diseases in patients with inflammatory bowel disease (ibd) have been reported with varying frequency, mostly from tertiary referral centers. the aim was to describe the spectrum of ophthalmologic conditions in patients with ibd in a community setting and to compare it

Predictive value of serologic markers in

Predictive value of serologic markers in a population-based norwegian cohort with inflammatory bowel disease

✍ Inger Camilla Solberg; Idar Lygren; Milada Cvancarova; Jørgen Jahnsen; Njaal Str 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB 👁 2 views

Background: Perinuclear antineutrophil cytoplasmic antibodies (pANCA) and anti-Saccharomyces cerevisiae antibodies (ASCA) are proposed to be specific markers for ulcerative colitis (UC) and Crohn's disease (CD). Their prevalence and relationship to disease phenotype and outcome in unselected cohorts

Complementary and alternative medicine i

Complementary and alternative medicine in patients with inflammatory bowel disease: The results of a population-based inception cohort study (IBSEN)

✍ Randi Opheim; Marte L. Hoivik; Inger C. Solberg; Bjorn Moum 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 414 KB

Adverse events leading to modification o

Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease

✍ U. HINDORF; M. LINDQVIST; H. HILDEBRAND; U. FAGERBERG; S. ALMER 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 230 KB

Systemic levels of free 5-aminosalicylic

Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease

✍ N. Mahmud; D. G. Weir; D. Kelleher 📂 Article 📅 1999 🏛 Springer-Verlag 🌐 English ⚖ 505 KB

Presentation and outcome of histoplasmos

Presentation and outcome of histoplasmosis in pediatric inflammatory bowel disease patients treated with antitumor necrosis factor alpha therapy: A case series

✍ Jennifer L. Dotson; Wallace Crandall; Hayat Mousa; Jonathan R. Honegger; Lee Den 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 326 KB 👁 1 views

Background: Antitumor necrosis factor alpha (aTNF) therapies are commonly used in the treatment of pediatric inflammatory bowel disease (IBD). However, inhibition of the TNF-alpha pathway predisposes to serious infections, including histoplasmosis, which is the most common invasive fungal infection